FGF19 and metabolic dysfunction-associated steatohepatitis: The demonstration that FXR agonists PX-102 in healthy subjects [32] or MET409 and Cilofexor in NASH patients [35,36] reduce bile acid synthesis, with no significant increase in circulating FGF19 concentration, indicates that the activation of hepatic FXR might inhibit bile acid synthesis independently of FGF19.